Please assess the completion status of the following clinical trial:

Trial Title: MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participant has a diagnosis of essential hypertension.~* Participant is not treated with antihypertensive medication and meets protocol-specified blood pressure criteria.~* Participant is treated with single antihypertensive medication, and meets protocol-specified blood pressure criteria.~* Participant is being treated with up to dual oral antihypertensive medications, and will be able to discontinue the prior antihypertensive medication.~* Participant has no clinically meaningful findings to be disqualified from the study at the discretion of the investigator.~Exclusion criteria:~* Regarding hypertension, participant is currently taking \> 2 antihypertensive medications.~* Participant has a history of significant multiple and/or severe allergies to ingredients of Nu-lotan or Preminent and thiazide drug or related drug (i.e., sulfonamide-containing chlortalidone medicines)~* Participant is, at the time of signing informed consent, a user of recreational or illicit drugs or a recent history within the last year of drug or alcohol abuse or dependence.~* Participant is pregnant or breastfeeding or expecting to conceive or has a positive pregnancy test at the screening visit.~* Participant is currently participating or has participated in a study with an investigational compound (except losartan at any doses) or device within 30 days of signing informed consent.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- MK-0954A (Type: EXPERIMENTAL): Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks.
- Losartan (Type: ACTIVE_COMPARATOR): Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).